MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development, both autologous and allogeneic. Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation, is currently in Phase III, but has already obtained a Conditional Marketing Authorization by the EU Commission in the 2nd half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, MolMed is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, received in March 2019 the authorization to start human clinical trials in onco-hematologic indications (AML and MM) , following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed is listed on the MTA of Borsa Italiana since 2008.
View Top Employees from MolMedWebsite | http://www.molmed.com |
Ticker | MLM |
Revenue | $18 million |
Employees | 118 (40 on RocketReach) |
Founded | 1996 |
Phone | +39 390 221 2771 |
Fax | +39 02 2127 7325 |
Technologies |
HTML,
PHP,
Google Analytics
+13 more
(view full list)
|
Industry | Business Services, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Education, Organizations, Medical Testing & Clinical Laboratories |
Web Rank | 3 Million |
Keywords | Biotechnology, Cancer Drugs, Solid Tumors, Genetic Testing |
Competitors | Diatos, Humacyte, ImmunoGen, Inc., Oncodesign Precision Medicine - OPM, PharmaMar |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 32541 Companies, NAICS Code 54 Companies, NAICS Code 3254 Companies, NAICS Code 5417 Companies |
Looking for a particular MolMed employee's phone or email?
The MolMed annual revenue was $18 million in 2024.
Antonio Lambiase is the Clinical Director of MolMed.
40 people are employed at MolMed.
MolMed is based in Milan, Lombardia.
The NAICS codes for MolMed are [32, 325, 541, 32541, 54, 3254, 5417].
The SIC codes for MolMed are [28, 283].